Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data

BACKGROUND: Patients with severe hemophilia A (SHA) in Italy are routinely treated with standard half-life recombinant factor VIII (rFVIII) products. rFVIII Fc-fusion protein (rFVIIIFc) is an extended half-life rFVIII product that enables less frequent administration than rFVIII, which may support i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bullement, Ash, McMordie, Samuel Thomas, Hatswell, Anthony James, Li, Nanxin, Wilson, Koo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018914/
https://www.ncbi.nlm.nih.gov/pubmed/31280415
http://dx.doi.org/10.1007/s41669-019-0158-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018914/
https://www.ncbi.nlm.nih.gov/pubmed/31280415
http://dx.doi.org/10.1007/s41669-019-0158-8

Ejemplares similares